Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 45

1.

Phase 2 study of pre-excision single-dose intraoperative radiation therapy for early-stage breast cancers: six-year update with application of the ASTRO accelerated partial breast irradiation consensus statement criteria.

Vanderwalde NA, Jones EL, Kimple RJ, Moore DT, Klauber-Demore N, Sartor CI, Ollila DW.

Cancer. 2013 May 1;119(9):1736-43. doi: 10.1002/cncr.27915. Epub 2013 Jan 29.

2.

Phase I study and biomarker analysis of lapatinib and concurrent radiation for locally advanced breast cancer.

Kimple RJ, Horton JK, Livasy CA, Shields JM, Lawrence JA, Chiu WM, Ivanova A, Ollila DW, Carey LA, Halle JS, Sartor CI, Dees EC.

Oncologist. 2012;17(12):1496-503. doi: 10.1634/theoncologist.2012-0256. Epub 2012 Sep 24.

3.

Local control following single-dose intraoperative radiotherapy prior to surgical excision of early-stage breast cancer.

Kimple RJ, Klauber-DeMore N, Kuzmiak CM, Pavic D, Lian J, Livasy CA, Chiu WM, Moore DT, Sartor CI, Ollila DW.

Ann Surg Oncol. 2011 Apr;18(4):939-45. doi: 10.1245/s10434-010-1392-6.

PMID:
21061074
4.

Lapatinib in combination with radiation diminishes tumor regrowth in HER2+ and basal-like/EGFR+ breast tumor xenografts.

Sambade MJ, Kimple RJ, Camp JT, Peters E, Livasy CA, Sartor CI, Shields JM.

Int J Radiat Oncol Biol Phys. 2010 Jun 1;77(2):575-81. doi: 10.1016/j.ijrobp.2009.12.063.

5.

Cosmetic outcomes for accelerated partial breast irradiation before surgical excision of early-stage breast cancer using single-dose intraoperative radiotherapy.

Kimple RJ, Klauber-DeMore N, Kuzmiak CM, Pavic D, Lian J, Livasy CA, Esler L, Moore DT, Sartor CI, Ollila DW.

Int J Radiat Oncol Biol Phys. 2011 Feb 1;79(2):400-7. doi: 10.1016/j.ijrobp.2009.10.032. Epub 2010 Apr 13.

6.

Radiosensitization of epidermal growth factor receptor/HER2-positive pancreatic cancer is mediated by inhibition of Akt independent of ras mutational status.

Kimple RJ, Vaseva AV, Cox AD, Baerman KM, Calvo BF, Tepper JE, Shields JM, Sartor CI.

Clin Cancer Res. 2010 Feb 1;16(3):912-23. doi: 10.1158/1078-0432.CCR-09-1324. Epub 2010 Jan 26.

8.

Radiosensitization of chemotherapy-refractory, locally advanced or locally recurrent breast cancer with trastuzumab: a phase II trial.

Horton JK, Halle J, Ferraro M, Carey L, Moore DT, Ollila D, Sartor CI.

Int J Radiat Oncol Biol Phys. 2010 Mar 15;76(4):998-1004. doi: 10.1016/j.ijrobp.2009.03.027. Epub 2009 Jun 27.

PMID:
19560883
9.

EGFR associated expression profiles vary with breast tumor subtype.

Hoadley KA, Weigman VJ, Fan C, Sawyer LR, He X, Troester MA, Sartor CI, Rieger-House T, Bernard PS, Carey LA, Perou CM.

BMC Genomics. 2007 Jul 31;8:258.

10.

The HER4 cytoplasmic domain, but not its C terminus, inhibits mammary cell proliferation.

Feng SM, Sartor CI, Hunter D, Zhou H, Yang X, Caskey LS, Dy R, Muraoka-Cook RS, Earp HS 3rd.

Mol Endocrinol. 2007 Aug;21(8):1861-76. Epub 2007 May 15.

11.

The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.

Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, Ollila DW, Sartor CI, Graham ML, Perou CM.

Clin Cancer Res. 2007 Apr 15;13(8):2329-34.

12.

In vivo intraoperative radiotherapy: a novel approach to radiotherapy for early stage breast cancer.

Stitzenberg KB, Klauber-Demore N, Chang XS, Calvo BF, Ollila DW, Goyal LK, Meyers MO, Kim HJ, Tepper JE, Sartor CI.

Ann Surg Oncol. 2007 Apr;14(4):1515-6.

PMID:
17235715
13.

Feasibility of breast preserving therapy with single fraction in situ radiotherapy delivered intraoperatively.

Ollila DW, Klauber-DeMore N, Tesche LJ, Kuzmiak CM, Pavic D, Goyal LK, Lian J, Chang S, Livasy CA, Sherron RF, Sartor CI.

Ann Surg Oncol. 2007 Feb;14(2):660-9.

PMID:
17091330
14.

Radiation therapy and biologics: a ripe opportunity?

Tepper JE, Sartor CI.

Nat Clin Pract Oncol. 2006 Sep;3(9):463. No abstract available.

PMID:
16955079
15.

Heregulin-dependent delay in mitotic progression requires HER4 and BRCA1.

Muraoka-Cook RS, Caskey LS, Sandahl MA, Hunter DM, Husted C, Strunk KE, Sartor CI, Rearick WA Jr, McCall W, Sgagias MK, Cowan KH, Earp HS 3rd.

Mol Cell Biol. 2006 Sep;26(17):6412-24.

16.

The ERBB4/HER4 intracellular domain 4ICD is a BH3-only protein promoting apoptosis of breast cancer cells.

Naresh A, Long W, Vidal GA, Wimley WC, Marrero L, Sartor CI, Tovey S, Cooke TG, Bartlett JM, Jones FE.

Cancer Res. 2006 Jun 15;66(12):6412-20.

17.

Axillary lymph node count is lower after neoadjuvant chemotherapy.

Neuman H, Carey LA, Ollila DW, Livasy C, Calvo BF, Meyer AA, Kim HJ, Meyers MO, Dees EC, Collichio FA, Sartor CI, Moore DT, Sawyer LR, Frank J, Klauber-DeMore N.

Am J Surg. 2006 Jun;191(6):827-9.

PMID:
16720159
18.

Size of residual lymph node metastasis after neoadjuvant chemotherapy in locally advanced breast cancer patients is prognostic.

Klauber-DeMore N, Ollila DW, Moore DT, Livasy C, Calvo BF, Kim HJ, Dees EC, Sartor CI, Sawyer LR, Graham M 2nd, Carey LA.

Ann Surg Oncol. 2006 May;13(5):685-91. Epub 2006 Mar 9.

PMID:
16523367
19.

Postmastectomy radiotherapy in intermediate-risk patients: the gray zone.

Sartor CI.

Curr Oncol Rep. 2006 Jan;8(1):29-34. Review.

PMID:
16464400
20.

Mechanisms of disease: Radiosensitization by epidermal growth factor receptor inhibitors.

Sartor CI.

Nat Clin Pract Oncol. 2004 Dec;1(2):80-7. Review.

PMID:
16264825
21.

Comparison of three concomitant boost techniques for early-stage breast cancer.

Horton JK, Halle JS, Chang SX, Sartor CI.

Int J Radiat Oncol Biol Phys. 2006 Jan 1;64(1):168-75. Epub 2005 Sep 29.

PMID:
16198507
22.

Staged sentinel lymph node biopsy before mastectomy facilitates surgical planning for breast cancer patients.

Klauber-Demore N, Calvo BF, Hultman CS, Kim HJ, Meyers MO, Damitz L, Frank JS, Stitzenberg KB, Sartor CI, Ollila DW.

Am J Surg. 2005 Oct;190(4):595-7.

PMID:
16164929
23.

American Joint Committee on Cancer tumor-node-metastasis stage after neoadjuvant chemotherapy and breast cancer outcome.

Carey LA, Metzger R, Dees EC, Collichio F, Sartor CI, Ollila DW, Klauber-DeMore N, Halle J, Sawyer L, Moore DT, Graham ML.

J Natl Cancer Inst. 2005 Aug 3;97(15):1137-42.

PMID:
16077072
24.

Inhibition of HER-2/neu kinase impairs androgen receptor recruitment to the androgen responsive enhancer.

Liu Y, Majumder S, McCall W, Sartor CI, Mohler JL, Gregory CW, Earp HS, Whang YE.

Cancer Res. 2005 Apr 15;65(8):3404-9.

25.

Clinical significance of micrometastatic disease in the era of sentinel node.

Ollila DW, Carey LA, Sartor CI.

Breast Dis. 2001;12:57-67. No abstract available.

PMID:
15687607
26.

Central nervous system metastases in women after multimodality therapy for high risk breast cancer.

Carey LA, Ewend MG, Metzger R, Sawyer L, Dees EC, Sartor CI, Moore DT, Graham ML.

Breast Cancer Res Treat. 2004 Dec;88(3):273-80.

PMID:
15609130
27.

Effect of addition of adjuvant paclitaxel on radiotherapy delivery and locoregional control of node-positive breast cancer: cancer and leukemia group B 9344.

Sartor CI, Peterson BL, Woolf S, Fitzgerald TJ, Laurie F, Turrisi AJ, Bogart J, Henderson IC, Norton L.

J Clin Oncol. 2005 Jan 1;23(1):30-40. Epub 2004 Nov 15.

PMID:
15545661
28.

High-resolution axillary ultrasound is a poor prognostic test for determining pathologic lymph node status in patients undergoing neoadjuvant chemotherapy for locally advanced breast cancer.

Klauber-Demore N, Kuzmiak C, Rager EL, Ogunrinde OB, Ollila DW, Calvo BF, Kim HJ, Meyer A, Dees C, Graham M 2nd, Collichio FA, Sartor CI, Metzger R, Carey LA.

Am J Surg. 2004 Oct;188(4):386-9.

PMID:
15474431
29.

Involvement of Ras activation in human breast cancer cell signaling, invasion, and anoikis.

Eckert LB, Repasky GA, Ulk├╝ AS, McFall A, Zhou H, Sartor CI, Der CJ.

Cancer Res. 2004 Jul 1;64(13):4585-92.

30.

Effects of the EGFR/HER2 kinase inhibitor GW572016 on EGFR- and HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance.

Zhou H, Kim YS, Peletier A, McCall W, Earp HS, Sartor CI.

Int J Radiat Oncol Biol Phys. 2004 Feb 1;58(2):344-52.

PMID:
14751502
31.
32.

The EGF receptor family--multiple roles in proliferation, differentiation, and neoplasia with an emphasis on HER4.

Earp HS 3rd, Calvo BF, Sartor CI.

Trans Am Clin Climatol Assoc. 2003;114:315-33; discussion 333-4. Review.

33.

Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741.

Citron ML, Berry DA, Cirrincione C, Hudis C, Winer EP, Gradishar WJ, Davidson NE, Martino S, Livingston R, Ingle JN, Perez EA, Carpenter J, Hurd D, Holland JF, Smith BL, Sartor CI, Leung EH, Abrams J, Schilsky RL, Muss HB, Norton L.

J Clin Oncol. 2003 Apr 15;21(8):1431-9. Epub 2003 Feb 13. Erratum in: J Clin Oncol. 2003 Jun 1;21(11):2226.

PMID:
12668651
34.

Epidermal growth factor family receptors and inhibitors: radiation response modulators.

Sartor CI.

Semin Radiat Oncol. 2003 Jan;13(1):22-30. Review.

PMID:
12520461
35.

Molecular targets as therapeutic strategies in the management of breast cancer.

Sartor CI.

Semin Radiat Oncol. 2002 Oct;12(4):341-51. Review.

PMID:
12382192
36.

Is less more? Lessons in radiation schedules in breast cancer.

Sartor CI, Tepper JE.

J Natl Cancer Inst. 2002 Aug 7;94(15):1114-5. No abstract available.

PMID:
12165629
38.
39.

Her4 mediates ligand-dependent antiproliferative and differentiation responses in human breast cancer cells.

Sartor CI, Zhou H, Kozlowska E, Guttridge K, Kawata E, Caskey L, Harrelson J, Hynes N, Ethier S, Calvo B, Earp HS 3rd.

Mol Cell Biol. 2001 Jul;21(13):4265-75.

40.

Biological modifiers as potential radiosensitizers: targeting the epidermal growth factor receptor family.

Sartor CI.

Semin Oncol. 2000 Dec;27(6 Suppl 11):15-20; discussion 92-100. Review.

PMID:
11236022
41.

Rate of PSA rise predicts metastatic versus local recurrence after definitive radiotherapy.

Sartor CI, Strawderman MH, Lin XH, Kish KE, McLaughlin PW, Sandler HM.

Int J Radiat Oncol Biol Phys. 1997 Jul 15;38(5):941-7.

PMID:
9276358
42.
44.

Interleukin-6 in psoriasis: expression and mitogenicity studies.

Elder JT, Sartor CI, Boman DK, Benrazavi S, Fisher GJ, Pittelkow MR.

Arch Dermatol Res. 1992;284(6):324-32.

45.

Supplemental Content

Loading ...
Support Center